{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T07:22:53Z","timestamp":1789456973508,"version":"build-2803163510"},"reference-count":94,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.beem.2022.101685","type":"journal-article","created":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T19:11:29Z","timestamp":1657998689000},"page":"101685","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Current medical treatment and perspective in gonadotroph tumors"],"prefix":"10.1016","volume":"36","author":[{"given":"Naomi","family":"Even-Zohar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yona","family":"Greenman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2022.101685_bib1","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s11060-013-1354-5","article-title":"Epidemiology and etiopathogenesis of pituitary adenomas","volume":"117","author":"Aflorei","year":"2014","journal-title":"J\u00a0Neuro Oncol"},{"key":"10.1016\/j.beem.2022.101685_bib2","series-title":"WHO classification of tumours of endocrine organs","first-page":"14","article-title":"Pituitary adenoma","author":"Osamura","year":"2017"},{"key":"10.1016\/j.beem.2022.101685_bib3","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1210\/jc.2018-00688","article-title":"Clinical and pathological aspects of silent pituitary adenomas","volume":"104","author":"Drummond","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101685_bib4","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s40618-020-01468-2","article-title":"The silent variants of pituitary tumors: demographic, radiological and molecular characteristics","volume":"44","author":"Torregrosa-Quesada","year":"2021","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.beem.2022.101685_bib5","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1210\/jcem.87.2.8145","article-title":"Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study","volume":"87","author":"Verg\u00e8s","year":"2002","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101685_bib6","doi-asserted-by":"crossref","first-page":"592","DOI":"10.4158\/EP.14.5.592","article-title":"Gonadotroph adenoma in multiple endocrine neoplasia type 1","volume":"14","author":"Sztal-Mazer","year":"2008","journal-title":"Endocr Pract"},{"key":"10.1016\/j.beem.2022.101685_bib7","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1210\/jc.2019-00082","article-title":"Clinical features of multiple endocrine neoplasia type 4: novel pathogenic variant and review of published cases","volume":"104","author":"Frederiksen","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101685_bib8","doi-asserted-by":"crossref","first-page":"E1103","DOI":"10.1210\/jc.2013-1400","article-title":"Familial SDHA mutation associated with pituitary adenoma and pheochromocytoma\/paraganglioma","volume":"98","author":"Dwight","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101685_bib9","doi-asserted-by":"crossref","first-page":"E663","DOI":"10.1210\/jc.2011-2291","article-title":"Germline AIP mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center cohort of 443 patients","volume":"97","author":"Cazabat","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101685_bib10","series-title":"MDText.com, Inc. Copyright \u00a9 2000-2022","article-title":"Endotext","author":"Stiles","year":"2000"},{"key":"10.1016\/j.beem.2022.101685_bib11","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/cr.2016.114","article-title":"The genome-wide mutational landscape of pituitary adenomas","volume":"26","author":"Song","year":"2016","journal-title":"Cell Res"},{"key":"10.1016\/j.beem.2022.101685_bib12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ccell.2019.11.002","article-title":"Pangenomic classification of pituitary neuroendocrine tumors","volume":"37","author":"Neou","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.beem.2022.101685_bib13","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11102-018-0869-3","article-title":"Epidemiology, clinical presentation and diagnosis of non-functioning pituitary adenomas","volume":"21","author":"Ntali","year":"2018","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2022.101685_bib14","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.jocn.2014.01.005","article-title":"Visual acuity and pattern of visual field loss at presentation in pituitary adenoma","volume":"21","author":"Ogra","year":"2014","journal-title":"J\u00a0Clin Neurosci"},{"key":"10.1016\/j.beem.2022.101685_bib15","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.beem.2009.05.005","article-title":"Non-functioning pituitary adenomas","volume":"23","author":"Greenman","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101685_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.lpm.2021.104086","article-title":"Clinically non-functioning pituitary adenomas","volume":"50","author":"Chanson","year":"2021","journal-title":"Presse Med"},{"key":"10.1016\/j.beem.2022.101685_bib17","article-title":"Presenting features in 269 patients with clinically nonfunctioning pituitary adenomas enrolled in a prospective study","volume":"4","author":"Freda","year":"2020","journal-title":"J\u00a0Endocr Soc"},{"key":"10.1016\/j.beem.2022.101685_bib18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12902-020-00677-3","article-title":"Successful pregnancy after operation in an infertile woman caused by luteinizing hormone-secreting pituitary adenoma: case report and literature review","volume":"21","author":"Zhang","year":"2021","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.beem.2022.101685_bib19","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2265.1998.00567.x","article-title":"The use of beta-subunits of gonadotrophin hormones in the follow-up of clinically non-functioning pituitary tumours","volume":"49","author":"Greenman","year":"1998","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2022.101685_bib20","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1210\/jc.2014-2362","article-title":"Clinical review: functioning gonadotroph adenomas","volume":"99","author":"Ntali","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101685_bib21","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s11102-017-0817-7","article-title":"Ovarian hyperstimulation syndrome due to follicle-stimulating hormone-secreting pituitary adenomas","volume":"20","author":"Caretto","year":"2017","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2022.101685_bib22","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/ncpendmet0758","article-title":"Ovarian hyperstimulation syndrome caused by an FSH-secreting pituitary adenoma","volume":"4","author":"Cooper","year":"2008","journal-title":"Nat Clin Pract Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101685_bib23","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.2169\/internalmedicine.52.7855","article-title":"Male gonadotroph adenoma: report of three cases and a review of the literature","volume":"52","author":"Tatsuoka","year":"2013","journal-title":"Intern Med"},{"key":"10.1016\/j.beem.2022.101685_bib24","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ando.2015.04.002","article-title":"Management of clinically non-functioning pituitary adenoma","volume":"76","author":"Chanson","year":"2015","journal-title":"Ann Endocrinol"},{"key":"10.1016\/j.beem.2022.101685_bib25","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1210\/jc.2010-1048","article-title":"Pituitary incidentaloma: an endocrine society clinical practice guideline","volume":"96","author":"Freda","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101685_bib26","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1227\/NEU.0000000000001386","article-title":"Congress of neurological surgeons systematic review and evidence-based guidelines on the management of patients with nonfunctioning pituitary adenomas: executive summary","volume":"79","author":"Aghi","year":"2016","journal-title":"Neurosurgery"},{"key":"10.1016\/j.beem.2022.101685_bib27","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1055\/a-1373-4087","article-title":"First German guideline on diagnostics and therapy of clinically non-functioning pituitary tumors","volume":"129","author":"Deutschbein","year":"2021","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.beem.2022.101685_bib28","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-17-0796","article-title":"European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas","volume":"178","author":"Raverot","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2022.101685_bib29","doi-asserted-by":"crossref","first-page":"R375","DOI":"10.1530\/ERC-20-0136","article-title":"The natural history and treatment of non-functioning pituitary adenomas (non-functioning PitNETs)","volume":"27","author":"Yavropoulou","year":"2020","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2022.101685_bib30","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/cen.12860","article-title":"Clinical outcomes in patients with nonfunctioning pituitary adenomas managed conservatively","volume":"83","author":"Sam","year":"2015","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2022.101685_bib31","doi-asserted-by":"crossref","first-page":"e1231","DOI":"10.1210\/clinem\/dgab748","article-title":"Nonfunctioning pituitary microadenomas: should imaging interval be extended? A large single-center cohort study","volume":"107","author":"Han","year":"2022","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101685_bib32","doi-asserted-by":"crossref","DOI":"10.1007\/s10143-022-01732-4","article-title":"Endoscopic vs. microscopic transsphenoidal surgery outcomes in 514 nonfunctioning pituitary adenoma cases","author":"Song","year":"2022","journal-title":"Neurosurg Rev"},{"key":"10.1016\/j.beem.2022.101685_bib33","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.ejso.2021.02.004","article-title":"Endoscopic transsphenoidal surgery reduces the need for re-operation compared to the microscopic approach in pituitary macroadenomas","volume":"47","author":"Shimony","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.beem.2022.101685_bib34","article-title":"Endoscopic vs. Microscopic transsphenoidal surgery for the treatment of pituitary adenoma: a meta-analysis","volume":"8","author":"Chen","year":"2021","journal-title":"Front Surg"},{"key":"10.1016\/j.beem.2022.101685_bib35","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11102-017-0854-2","article-title":"Management of non-functioning pituitary adenomas: surgery","volume":"21","author":"Penn","year":"2018","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2022.101685_bib36","doi-asserted-by":"crossref","unstructured":"Jiang S, Zhu J, Feng M, et\u00a0al. Clinical profiles of silent corticotroph adenomas compared with silent gonadotroph adenomas after adopting the 2017 WHO pituitary classification system. Pituitary 24, 564-573, doi:10.1007\/s11102-021-01133-8 (2021).","DOI":"10.1007\/s11102-021-01133-8"},{"key":"10.1016\/j.beem.2022.101685_bib37","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.3171\/2020.3.FOCUS20114","article-title":"Clinical characteristics and outcomes of null-cell versus silent gonadotroph adenomas in a series of 1166 pituitary adenomas from a single institution","volume":"48","author":"Haddad","year":"2020","journal-title":"Neurosurg Focus"},{"key":"10.1016\/j.beem.2022.101685_bib38","doi-asserted-by":"crossref","first-page":"e241","DOI":"10.1016\/j.wneu.2018.08.043","article-title":"Nonfunctioning pituitary adenoma recurrence and its relationship with sex, size, and hormonal immunohistochemical profile","volume":"120","author":"Batista","year":"2018","journal-title":"World Neurosurg"},{"key":"10.1016\/j.beem.2022.101685_bib39","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s12020-017-1447-6","article-title":"Clinical profile of silent growth hormone pituitary adenomas; higher recurrence rate compared to silent gonadotroph pituitary tumors, a large single center experience","volume":"58","author":"Langlois","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2022.101685_bib40","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s007010200064","article-title":"Magnetic resonance imaging after transsphenoidal surgery of clinically non-functional pituitary macroadenomas and its impact on detecting residual adenoma","volume":"144","author":"Kremer","year":"2002","journal-title":"Acta Neurochir"},{"key":"10.1016\/j.beem.2022.101685_bib41","doi-asserted-by":"crossref","first-page":"E541","DOI":"10.1227\/NEU.0000000000001392","article-title":"Congress of neurological surgeons systematic review and evidence-based guideline on posttreatment follow-up evaluation of patients with nonfunctioning pituitary adenomas","volume":"79","author":"Ziu","year":"2016","journal-title":"Neurosurgery"},{"key":"10.1016\/j.beem.2022.101685_bib42","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000339823","article-title":"Natural history of postoperative nonfunctioning pituitary adenomas: a systematic review and meta-analysis","volume":"96","author":"Chen","year":"2012","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.beem.2022.101685_bib43","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1046\/j.1365-2265.2003.01784.x","article-title":"Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumour quiescence and regrowth","volume":"58","author":"Greenman","year":"2003","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2022.101685_bib44","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ecl.2014.10.001","article-title":"A\u00a0prognostic clinicopathologic classification of pituitary endocrine tumors","volume":"44","author":"Raverot","year":"2015","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.beem.2022.101685_bib45","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1210\/jc.2017-00773","article-title":"Risk of recurrence in pituitary neuroendocrine tumors: a prospective study using a five-tiered classification","volume":"102","author":"Raverot","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101685_bib46","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1007\/s11102-019-00982-8","article-title":"Predictive modeling for pituitary adenomas: single center experience in 501 consecutive patients","volume":"22","author":"Pappy","year":"2019","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2022.101685_bib47","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s12020-018-1679-0","article-title":"The role of E and N-cadherin in the postoperative course of gonadotroph pituitary tumours","volume":"62","author":"\u00d8ystese","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2022.101685_bib48","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.endonu.2012.09.005","article-title":"Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness","volume":"60","author":"S\u00e1nchez-Tejada","year":"2013","journal-title":"Endocrinol Nutr"},{"key":"10.1016\/j.beem.2022.101685_bib49","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1210\/jc.2017-00792","article-title":"Estrogen receptor \u03b1, a sex-dependent predictor of aggressiveness in nonfunctioning pituitary adenomas: SSTR and sex hormone receptor distribution in NFPA","volume":"102","author":"\u00d8ystese","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101685_bib50","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2016-4061","article-title":"Outcome of nonfunctioning pituitary adenomas that regrow after primary treatment: a study from two large UK centers","volume":"102","author":"Tampourlou","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101685_bib51","doi-asserted-by":"crossref","first-page":"D1","DOI":"10.1530\/EJE-19-0058","article-title":"Use of radiotherapy after pituitary surgery for non-functioning pituitary adenomas","volume":"181","author":"Chanson","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2022.101685_bib52","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s13014-016-0710-y","article-title":"Target delineation and optimal radiosurgical dose for pituitary tumors","volume":"11","author":"Minniti","year":"2016","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.beem.2022.101685_bib53","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1042-3680(02)00031-1","article-title":"Radiotherapy and stereotactic radiosurgery for pituitary tumors","volume":"14","author":"Petrovich","year":"2003","journal-title":"Neurosurg Clin"},{"key":"10.1016\/j.beem.2022.101685_bib54","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.rpor.2014.09.004","article-title":"Stereotactic radiotherapy and radiosurgery for non-functioning and secreting pituitary adenomas","volume":"21","author":"Minniti","year":"2016","journal-title":"Rep Practical Oncol Radiother"},{"key":"10.1016\/j.beem.2022.101685_bib55","series-title":"Radiotherapy for Pituitary Tumors","author":"Kosmin","year":"2000"},{"key":"10.1016\/j.beem.2022.101685_bib56","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s11102-011-0316-1","article-title":"Dopamine 2 receptor expression in various pathological types of clinically non-functioning pituitary adenomas","volume":"15","author":"Gabalec","year":"2012","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2022.101685_bib57","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2265.1989.tb01418.x","article-title":"Bromocriptine therapy for non-functioning pituitary adenoma","volume":"30","author":"van Schaardenburg","year":"1989","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2022.101685_bib58","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/BF03350660","article-title":"Effect of chronic bromocriptine administration on tumor size in patients with \u201cnonsecreting\u201d pituitary adenomas","volume":"8","author":"Verde","year":"1985","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.beem.2022.101685_bib59","doi-asserted-by":"crossref","first-page":"281","DOI":"10.7326\/0003-4819-96-3-281","article-title":"Size reduction of extrasellar pituitary tumors during bromocriptine treatment","volume":"96","year":"1982","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.beem.2022.101685_bib60","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/COC.0000000000000505","article-title":"Cabergoline in the management of residual nonfunctioning pituitary adenoma: a single-center, open-label, 2-year randomized clinical trial","volume":"42","author":"Batista","year":"2019","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.beem.2022.101685_bib61","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11102-012-0403-y","article-title":"Short-term treatment with cabergoline can lead to tumor shrinkage in patients with nonfunctioning pituitary adenomas","volume":"16","author":"Garcia","year":"2013","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2022.101685_bib62","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1530\/EJE-16-0206","article-title":"Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists","volume":"175","author":"Greenman","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2022.101685_bib63","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1023\/A:1015366923810","article-title":"Minor tumour shrinkage in nonfunctioning pituitary adenomas by long-term treatment with the dopamine agonist cabergoline","volume":"4","author":"Lohmann","year":"2001","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2022.101685_bib64","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1210\/jc.2003-030859","article-title":"Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment","volume":"89","author":"Pivonello","year":"2004","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101685_bib65","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/cen.12684","article-title":"Dopamine receptor subtype 2 expression profile in nonfunctioning pituitary adenomas and in\u00a0vivo response to cabergoline therapy","volume":"82","author":"Vieira Neto","year":"2015","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2022.101685_bib66","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1530\/ERC-14-0472","article-title":"SSTR3 is a putative target for the medical treatment of gonadotroph adenomas of the pituitary","volume":"22","author":"Lee","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2022.101685_bib67","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11154-008-9107-z","article-title":"Medical therapy of pituitary adenomas: effects on tumor shrinkage","volume":"10","author":"Colao","year":"2008","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.beem.2022.101685_bib68","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s11102-011-0370-8","article-title":"Treatment with octreotide LAR in clinically non-functioning pituitary adenoma: results from a case-control study","volume":"15","author":"Fusco","year":"2012","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2022.101685_bib69","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1158\/1078-0432.CCR-19-2154","article-title":"A\u00a0somatostatin receptor subtype-3 (SST(3)) peptide agonist shows antitumor effects in experimental models of nonfunctioning pituitary tumors","volume":"26","author":"V\u00e1zquez-Borrego","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beem.2022.101685_bib70","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13123097","article-title":"Gender-specific efficacy revealed by head-to-head comparison of pasireotide and octreotide in a representative in\u00a0vivo model of nonfunctioning pituitary tumors","volume":"13","author":"Gulde","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.beem.2022.101685_bib71","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000500812","article-title":"A\u00a0new generation somatostatin-dopamine analogue exerts potent antitumoral actions on pituitary neuroendocrine tumor cells","volume":"110","author":"V\u00e1zquez-Borrego","year":"2020","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.beem.2022.101685_bib72","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.canlet.2009.06.034","article-title":"The dopamine-somatostatin chimeric compound BIM-23A760 exerts antiproliferative and cytotoxic effects in human non-functioning pituitary tumors by activating ERK1\/2 and p38 pathways","volume":"288","author":"Peverelli","year":"2010","journal-title":"Cancer Lett"},{"key":"10.1016\/j.beem.2022.101685_bib73","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqaa101","article-title":"TBR-760, a dopamine-somatostatin compound, arrests growth of aggressive nonfunctioning pituitary adenomas in mice","volume":"161","author":"Halem","year":"2020","journal-title":"Endocrinology"},{"key":"10.1016\/j.beem.2022.101685_bib74","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s11102-020-01113-4","article-title":"Characterization of the ability of a, second-generation SST-DA chimeric molecule, TBR-065, to suppress GH secretion from human GH-secreting adenoma cells","volume":"24","author":"Cuny","year":"2021","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2022.101685_bib75","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s11102-016-0745-y","article-title":"How effective is temozolomide for treating pituitary tumours and when should it be used?","volume":"20","author":"Halevy","year":"2017","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2022.101685_bib76","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1530\/EJE-17-0933","article-title":"Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016","volume":"178","author":"McCormack","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2022.101685_bib77","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1530\/EC-19-0065","article-title":"Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience","volume":"8","author":"Giuffrida","year":"2019","journal-title":"Endocr Connect"},{"key":"10.1016\/j.beem.2022.101685_bib78","article-title":"Emerging and novel treatments for pituitary tumors","volume":"8","author":"Ilie","year":"2019","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.beem.2022.101685_bib79","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/RLU.0000000000000589","article-title":"The use of (68)Ga DOTATATE PET\/CT for diagnostic assessment and monitoring of (177)Lu DOTATATE therapy in pituitary carcinoma","volume":"40","author":"Novruzov","year":"2015","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.beem.2022.101685_bib80","first-page":"30","article-title":"Functioning pituitary adenomas - current treatment options and emerging medical therapies","volume":"15","author":"Varlamov","year":"2019","journal-title":"Eur Endocrinol"},{"key":"10.1016\/j.beem.2022.101685_bib81","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ando.2018.11.007","article-title":"Functioning gonadotroph adenoma with severe ovarian hyperstimulation syndrome: a new emergency in pituitary adenoma surgery? Surgical considerations and literature review","volume":"80","author":"Graillon","year":"2019","journal-title":"Ann Endocrinol"},{"key":"10.1016\/j.beem.2022.101685_bib82","first-page":"591","article-title":"Gonadotroph adenoma in a premenopausal woman secreting follicle-stimulating hormone and causing ovarian hyperstimulation","volume":"80","author":"Djerassi","year":"1995","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101685_bib83","doi-asserted-by":"crossref","first-page":"719.e715","DOI":"10.1016\/j.fertnstert.2006.01.055","article-title":"Effectiveness of treating ovarian hyperstimulation syndrome with cabergoline in two patients with gonadotropin-producing pituitary adenomas","volume":"86","author":"Knoepfelmacher","year":"2006","journal-title":"Fertil Steril"},{"key":"10.1016\/j.beem.2022.101685_bib84","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000284395","article-title":"Spontaneous ovarian hyperstimulation syndrome caused by a follicle-stimulating hormone-secreting pituitary macroadenoma in an early pubertal girl","volume":"73","author":"Gryngarten","year":"2010","journal-title":"Horm Res Paediatr"},{"key":"10.1016\/j.beem.2022.101685_bib85","doi-asserted-by":"crossref","first-page":"199","DOI":"10.14310\/horm.2002.1347","article-title":"Gonadotroph pituitary macroadenoma inducing ovarian hyperstimulation syndrome: successful response to octreotide therapy","volume":"11","author":"Karapanou","year":"2012","journal-title":"Hormones (Athens)"},{"key":"10.1016\/j.beem.2022.101685_bib86","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/BF03401328","article-title":"Gonadotropin secreting pituitary adenoma associated with erythrocytosis: case report and literature review","volume":"13","author":"Ceccato","year":"2014","journal-title":"Hormones (Athens)"},{"key":"10.1016\/j.beem.2022.101685_bib87","first-page":"2267","article-title":"Pituitary apoplexy caused by GnRH-agonist treatment revealing gonadotroph adenoma","volume":"80","author":"Chanson","year":"1995","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101685_bib88","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0015-0282(02)04342-X","article-title":"Exacerbation of ovarian hyperstimulation by leuprolide reveals a gonadotroph adenoma","volume":"78","author":"Castelbaum","year":"2002","journal-title":"Fertil Steril"},{"key":"10.1016\/j.beem.2022.101685_bib89","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.fertnstert.2011.10.015","article-title":"A\u00a0pituitary adenoma secreting follicle-stimulating hormone with ovarian hyperstimulation: treatment using a gonadotropin-releasing hormone antagonist","volume":"97","author":"Garmes","year":"2012","journal-title":"Fertil Steril"},{"key":"10.1016\/j.beem.2022.101685_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.yfrne.2020.100852","article-title":"The tumour microenvironment of pituitary neuroendocrine tumours","volume":"58","author":"Marques","year":"2020","journal-title":"Front Neuroendocrinol"},{"key":"10.1016\/j.beem.2022.101685_bib91","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.608422","article-title":"The progress of immunotherapy in refractory pituitary adenomas and pituitary carcinomas","volume":"11","author":"Dai","year":"2020","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.beem.2022.101685_bib92","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41574-021-00550-w","article-title":"Aggressive pituitary tumours and pituitary carcinomas","volume":"17","author":"Raverot","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.beem.2022.101685_bib93","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12957-021-02272-9","article-title":"Research advances on the immune research and prospect of immunotherapy in pituitary adenomas","volume":"19","author":"Nie","year":"2021","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.beem.2022.101685_bib94","doi-asserted-by":"crossref","first-page":"D11","DOI":"10.1530\/EJE-21-0344","article-title":"Cabergoline should be attempted in progressing non- functioning pituitary macroadenoma","volume":"185","author":"Greenman","year":"2021","journal-title":"Eur J Endocrinol"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X22000720?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X22000720?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:59:28Z","timestamp":1761497968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X22000720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":94,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1521690X22000720"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2022.101685","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current medical treatment and perspective in gonadotroph tumors","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2022.101685","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101685"}}